Safety and Efficacy Study of ONGLYZA (Saxagliptin) Under Conditions of Actual Use (ONGLYZA PMS)

AstraZeneca

Status: Terminated

Conditions: Type 2 Diabetes Mellitus

Study type: Observational

Funder types: Industry

Identifiers

NCT01223456

NIS-CPH-DUM-2010/1

Details and patient eligibility

About

This post marketing surveillance study aims to monitor the safety and efficacy of ONGLYZA under conditions of actual use in patients who are diagnosed with diabetes mellitus type 2 and are prescribed ONGLYZA by their physician.

Enrollment: 542 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Type 2 Diabetes Mellitus
• Prescribed Saxagliptin by patient's attending physician

Exclusion criteria

• Known allergic or serious adverse reaction to Saxagliptin
• Pregnant or breastfeeding patients